We believe that our mouse model is particularly attractive for pre-clinical drug development because of the ease with which de novo medulloblastoma tumors develop in Pten deficient mice and because of the difference in tumor histology between the two mouse models. This evidence concerns the gene PTEN and medulloblastoma.